Delving into the Latest Updates on UCB Korea Co., Ltd. with Synapse

Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.

开始日期2012-04-01

申办/合作机构

UCB Korea Co., Ltd.

NCT01498822

/ Completed临床4期

A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy

To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks from the first dose

开始日期2011-06-01

申办/合作机构

UCB Korea Co., Ltd.

NCT02101710

/ Completed临床1期

A Randomized, Open-label, One Dose, 2-way Crossover Study to Evaluate the Bioequivalence of Elantan SR* 60 mg in Comparison With Imdur SR* 60 mg Under Fasted and Fed Conditions in Healthy Korean Male Subjects (*Sustained Release)

This study it to evaluate the bioequivalence of Elantan SR 60 mg compared to Imdur SR 60 mg in sixty healthy Korean male subjects.

开始日期2011-06-01

申办/合作机构

UCB Korea Co., Ltd.

[+1]

100 项与 UCB Korea Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 UCB Korea Co., Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 UCB Korea Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 UCB Korea Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年04月19日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

泽勒普肽 ( C5 )	重症肌无力更多	批准上市
比奇珠单抗 ( IL-17A x IL-17F )	斑块状银屑病更多	批准上市
布立西坦 ( SV2A )	癫痫部分性发作更多	批准上市